Alimera Sciences Inc expected to post a loss of 6 cents a share - Earnings Preview

Alimera Sciences

10/05/2024 14:59

* Alimera Sciences Inc  ALIM.OQ   ALIM.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 14 for
the period ending March 31 2024
    * The Alpharetta Georgia-based  company is expected to
report a
64.3% increase in revenue to $22.25 million from $13.55 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Alimera Sciences Inc is
for a
loss of 6 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The average consensus recommendation for
the pharmaceuticals
peer group is also "Buy".​
    * Wall Street's median 12-month price target for Alimera
Sciences
Inc is $8.00​, above​ its last closing price of $3.38. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023              0.00       -0.07     Missed  
 Sep. 30 2023  0.00        -0.06      -0.06     Met     7
 Jun. 30 2023  0.00        0.02       -1.32     Missed  -8,900
                                                        ​
 Mar. 31 2023  -0.51       -0.32      -0.71     Missed  -121.9
 ​​Dec.                    -0.33      -0.54     Missed  -61.2
 31 2022                                                
 Jan. 1 0001   -0.40       -0.40      -0.75     Missed  -86​
 Jun. 30 2022  -0.55       -0.55      -0.45     Beat    18.7
 Jan. 1 0001   -0.69       -0.69      -0.85     Missed  -23.2
 This summary was machine generated May 10 at 13:59 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)